Navigation Links
Accelerated search for active agents to treat Alzheimer's and Parkinson's
Date:2/24/2012

Professor Erich Wanker of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and of the Excellence Cluster Neurocure is to receive EUR 675 000 in funding from the Helmholtz Association over the next two years. The grant shall be used to accelerate the search for active agents to treat diseases that are caused by protein misfolding. These include Alzheimer's and Parkinson's. The grant amount will be matched by the MDC, a member institution of the Helmholtz Association, which means that the total funding for the research project will be EUR 1.35 million.

The grant shall be used to develop a standardized screening platform for the identification of active agents that can be utilized by the pharmaceutical industry. The project is intended to result in the establishment of a spin-off company. The key element will be a system to identify active agents that impact protein aggregates that are toxic for brain cells. Protein aggregation plays a significant role in common neurological diseases such as Alzheimer's and Parkinson's or the rare Huntington's disease. In the pathogenesis of these diseases, a misfolding of specific proteins occurs in the brain cells, leading to an aggregation of harmful structures that cannot be disposed of. This increasingly leads to degeneration of the brain cells in the affected individuals and subsequently depending on the protein and the disease to memory loss, movement disorders, psychosis and dementia. Altogether, about 40 diseases can be attributed to protein misfolding, including diabetes mellitus.

The research group of Professor Wanker has been studying protein misfolding for over ten years and has developed innovative concepts and methods to test active agents for their capacity to intervene in protein misfolding processes. One of the group's discoveries is that epigallocatechin-3-gallate (EGCG), a green tea extract, binds to toxic misfolded products and modulates these into nontoxic structures.

The methods hitherto used by the group shall now be incorporated into a technology platform to test larger libraries of potential active agents. This will include a high-throughput robotic system developed by the researchers for investigating interactions among proteins but also between proteins and other substances. In 2008 they received the Erwin Schrdinger Prize for research in this area.

The new Helmholtz Validation Fund, according to the Helmholtz Association announcement, will also fund a project of the Helmholtz Center Dresden-Rossendorf and the Research Center Jlich. The aim of this project is to improve imaging techniques for drug development to treat Alzheimer's.

Until 2015 the Initiative and Networking Fund of the Helmholtz Association has allocated a total of EUR 26 million to the Helmholtz Validation Fund to fund projects at Helmholtz centers. Including the matching funds from the centers, more than EUR 50 million will be available for technology transfer projects.


'/>"/>

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Concordia research accelerated
2. Accelerated lab evolution of biomolecules could yield new generation of medicines
3. Study finds link between chronic depression and accelerated immune cell aging
4. New year, new vitamin C discovery: It cures mice with accelerated aging disease
5. Geological cycle causes biodiversity booms and busts every 60 million years, research suggests
6. UC Santa Barbara researchers new study may lead to MRIs on a nanoscale
7. Research examines environmental triggers altering gene function in CFS patients
8. Researchers discover how vitamin D inhibits inflammation
9. Study finds college students willing to donate genetic material to biobanks for research
10. Purdue researchers reveal role of protein mutation in Parkinsons disease
11. Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
Breaking Biology Technology: